The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.
Ook interessant voor je
Reageer